Oral spray vaccine prevents recurring UTIs for up to 9 years

A British trial showed an oral spray vaccine can prevent recurring UTIs for up to nine years, benefiting those facing 150,000 annual hospitalizations costing the NHS £380 million. Half of women and 20% of men suffer from UTIs, with a death rate of 6,000 annually. The vaccine, Uromune, led to 48% remaining infection-free for nine years, with an average infection-free period of 54.7 months.